Lunit (A328130) Stock Overview
Provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A328130 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lunit Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,180.00 |
| 52 Week High | ₩30,350.00 |
| 52 Week Low | ₩15,900.00 |
| Beta | 1.31 |
| 1 Month Change | -10.05% |
| 3 Month Change | -15.58% |
| 1 Year Change | -28.12% |
| 3 Year Change | -18.00% |
| 5 Year Change | n/a |
| Change since IPO | 71.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| A328130 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | 1.4% | 5.2% | 13.5% |
| 1Y | -28.1% | 19.0% | 190.8% |
Return vs Industry: A328130 underperformed the KR Healthcare Services industry which returned 23.2% over the past year.
Return vs Market: A328130 underperformed the KR Market which returned 188.7% over the past year.
Price Volatility
| A328130 volatility | |
|---|---|
| A328130 Average Weekly Movement | 10.3% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in KR Market | 16.6% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A328130 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A328130's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 307 | Beomseok Brandon Suh | www.lunit.io |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research.
Lunit Inc. Fundamentals Summary
| A328130 fundamental statistics | |
|---|---|
| Market cap | ₩1.28t |
| Earnings (TTM) | -₩67.09b |
| Revenue (TTM) | ₩87.88b |
Is A328130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A328130 income statement (TTM) | |
|---|---|
| Revenue | ₩87.88b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩87.88b |
| Other Expenses | ₩154.97b |
| Earnings | -₩67.09b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -901.97 |
| Gross Margin | 100.00% |
| Net Profit Margin | -76.34% |
| Debt/Equity Ratio | 104.4% |
How did A328130 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 02:35 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lunit Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Choi | Macquarie Research |
| Hyun-soo Ha | Yuanta Securities Korea Co., Ltd. |